- Home
- HBCP vs EBS Comparison
HBCP vs EBS Comparison
Compare HBCP & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBCP | EBS |
|---|---|---|
| Founded | 1908 | 1998 |
| Country | United States | United States |
| Employees | N/A | 900 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 473.7M |
| IPO Year | 2008 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HBCP | EBS |
|---|---|---|
| Price | $64.47 | $9.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $65.50 | $12.00 |
| AVG Volume (30 Days) | 62.3K | ★ 729.6K |
| Earning Date | 04-20-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | 29.01 | ★ 125.83 |
| EPS | ★ 1.45 | 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | ★ $44.50 | $131.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.30 | $5.62 |
| 52 Week High | $66.00 | $14.06 |
Technical Indicators
Market Signals| Indicator | HBCP | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 59.41 |
| Support Level | $61.84 | $9.00 |
| Resistance Level | $65.86 | $9.66 |
| Average True Range (ATR) | 1.34 | 0.42 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 62.34 | 69.71 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.